[O13] Oral Session 13　Lung Cancer / Thoracic Cancer 3（Rare gene alterations）
【E】

[O13-6] Japanese Subgroup Analysis of Datopotamab Deruxtecan in NSCLC Cohort of TROPION-PanTumor01, a Phase 1 Study

^○Toshio Shimizu¹, Satoru Kitazono², Edward B Garon³, Melissa L Johnson⁴, Aaron Lisberg³, Alexander Spira⁵, Noboru Yamamoto¹, Rebecca S Heist⁶, Jacob M Sands⁷, Funda Meric-Bernstam⁸, Yoshitaka Zenke⁹, Noriko Yanagitani², Jonathan Greenberg¹⁰, Fumiaki Kobayashi¹¹, Yui Kawasaki¹¹, Kiyotaka Yoh⁹ (1.National Cancer Center Hospital, Tokyo, Japan, 2.The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 3.David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 4.Sarah Cannon Research Institute, Tennessee Oncology, PLLC, One Oncology, Nashville, TN, USA, 5.Virginia Cancer Specialists and US Oncology Research, Fairfax, VA, USA, 6.Massachusetts General Hospital, Boston, MA, USA, 7.Dana-Farber Cancer Institute, Boston, MA, USA, 8.The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 9.National Cancer Center Hospital East, Chiba, Japan, 10.Daiichi Sankyo, Inc, Basking Ridge, NJ, USA, 11.Daiichi Sankyo Co, Ltd, Tokyo, Japan)